What bDMARD would you choose for a patient with RA with high infection risk and inadequate response to cDMARDs?  

This is an important question and a prime example of the "art of rheumatology" where we must balance the risk and benefit of targeted therapies of treating active RA and adverse events such as serious infection. Ideally, we would have many head-to-head trials of every agent adequately powered to ans...